Valerio Therapeutics
0.40
EUR
-0.01
(-1.86%)
Valerio Therapeutics
GETTEX:C4X
(Gettex)
Recent
price
0.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.- Similar Companies
- Business
- Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) is a clinical-stage biotechnology company that develops precision-guided therapeutics targeting complex and underserved diseases, including oncology and inflammatory disorders, through its proprietary V-Body platform of fully synthetic single-domain antibodies (sdAbs) and complementary chemistry capabilities; the V-Body platform, comprising human VH-derived and fully humanized VHH libraries (~15 kDa), enables deep tissue penetration, high specificity, and targeted delivery via drug conjugates, radio-conjugates, bispecific T-cell engagers, blocking sdAbs, and CAR-T sdAb drugs; additional offerings include the PlatON platform for DecoyTAC molecules combining cell-penetrating DNA decoys with linker-E3 ligands. The company focuses on advancing candidates from preclinical stages to proof-of-concept before strategic partnerships, co-development, or out-licensing, serving target markets in autoimmune diseases, inflammation, and solid tumors such as HRD+ ovarian cancer and HRRm/HRD+ tumors. Founded in 1997 and headquartered at 49 Boulevard du Général Martial Valin, Paris, France, Valerio Therapeutics operates primarily in Europe with prior U.S. presence now closed. In recent developments, Valerio Therapeutics acquired Emglev Therapeutics in September 2024 through its subsidiary Valour Bio to integrate proprietary sdAb technology, enhancing multimodal therapeutic development; the company discontinued all clinical trials, including the Phase 1/2 VIO-01 pan-DDR DNA decoy study in February 2025 amid financing challenges, shifting focus exclusively to early-stage research on its single-chain antibody platform combined with oligonucleotides and chemistry expertise; it closed its U.S. office in Lexington, MA, as part of this strategic refocus to ensure financial sustainability. Further restructuring includes a proposed simplified merger with Valour Bio (90.01%-owned), following Valour Bio's absorption of Emglev, to streamline the group structure effective retroactively from January 1, 2025, with approval pending Valour Bio shareholder vote in December 2025; additional actions encompass a capital increase with cancelled preferential rights in October 2025, share capital transactions to restructure liabilities in July 2025, and board composition changes in November 2025.